OAM
ARGS

Oxford Asset Management’s Argos Therapeutics, Inc. ARGS Stock Holding History

Oxford Asset Management’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2,882
Closed -$353K – 970
2016
Q2 		$353K Buy
+2,882
New +$385K 0.01% 637

Other funds holding ARGS

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
AGA
Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Oxford Asset Management's ARGS Position: Q3 2016 in Review

Oxford Asset Management sold out of Argos Therapeutics, Inc. (ARGS) in Q3 2016, closing a stake of 2,882 shares — an estimated $353K sold.

Oxford Asset Management first reported a position in ARGS in Q2 2016 and held it in 1 quarter. The position peaked at $353K in Q2 2016. 46 funds tracked by Wall St. Rank hold ARGS as of Q3 2016.

  • Oxford Asset Management reported no remaining Argos Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Oxford Asset Management sold 2,882 Argos Therapeutics, Inc. shares in Q3 2016, an estimated $353K.
  • Oxford Asset Management first reported a position in Argos Therapeutics, Inc. in Q2 2016 and held it in 1 quarter.
  • Oxford Asset Management's Argos Therapeutics, Inc. position peaked at $353K in Q2 2016.
  • 46 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q3 2016.

Based on Oxford Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.